Search filters

List of works by Adam Patterson

2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).

scientific article published on 30 July 2015

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

scientific article published on March 2004

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors

scientific article published on 31 March 2017

2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors

scientific article published on 22 April 2017

3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.

scientific article published on October 2003

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

scientific article

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

scientific article

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

scholarly article

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

scientific article

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol

scientific article published on 23 March 2020

Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.

scientific article

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

scientific article published in December 2015

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

scientific article published on 12 July 2013

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

scientific article published on June 2007

Bystander or no bystander for gene directed enzyme prodrug therapy

scientific article

Can gene therapy overcome the problem of hypoxia in radiotherapy?

scientific article

Cancer chemotherapy and drug metabolism.

scientific article published in August 2005

Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro

scientific article

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.

scientific article published on 16 April 2014

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

scientific article published in March 2010

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

scientific article

Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.

scientific article published on March 2004

DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.

scientific article

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine

scientific article published on January 2004

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents

scientific article published in June 2021

Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia

scientific article published on 7 October 2011

Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug

scientific article published on 26 August 2020

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

scientific article

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer

scientific article published on 6 February 2018

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

scientific article published on December 1999

Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.

scientific article published in May 2005

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

scientific article published on 21 August 2020

Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy

scientific article published on 20 August 2019

Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.

scientific article published on 20 February 2017

Enzymology of tirapazamine metabolism: a review

scientific article published on 01 September 1998

Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy

scientific article published on 21 October 2018

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy, Advances and Prospects

scientific article published on 16 November 2018

Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis

scientific article published on 2 November 2016

Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines ⬇️

scientific article published on October 15, 2003

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

scientific article published on 18 January 2019

Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia

scientific article

Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5

scientific article published on 15 August 2014

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

scientific article published on November 1995

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase

scientific article

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

scientific article published in February 2022

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

scientific article

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

scientific article

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors

scientific article published on 18 March 2015

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

scientific article

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

scientific article published on 6 October 2009

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

scientific article published on October 2015

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.

scientific article published in October 2002

Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

scientific article published on October 2008

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 ⬇️

scientific article published on January 1, 1997

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine

scientific article published on 01 October 2007

Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours

scientific article published on July 2002

Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs

scientific article published in December 2004

Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML ⬇️

scholarly article

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

scientific article

Prodrugs in genetic chemoradiotherapy.

scientific article published on January 2003

Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study

scientific article published on 13 March 2019

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy

scientific article published on 10 June 2013

Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator

scientific article published on 14 March 2006

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy

scientific article

Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.

scientific article

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

scientific article published on 26 November 2021

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.

scientific article

Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4

scientific article published on 03 July 2019

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

scientific article published on 8 October 2021

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.

scientific article published on July 2012

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase

scientific article published in October 2009

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623

scientific article published on 15 June 2024

Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine

scientific article

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

scientific article published on 22 October 2020

Synthesis and antiproliferative activity of C- and N-terminal analogues of culicinin D

scientific article published on 09 June 2020

Synthesis and antiproliferative activity of culicinin D analogues containing simplified AHMOD-based residues

scientific article published on 23 May 2019

Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.

scientific article published in December 2013

Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy

scientific article published on 28 February 2007

TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

scientific article published on 14 January 2019

Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954.

scientific article

Targeting gene expression to hypoxic tumor cells

article

Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

scientific article published on 22 December 2020

The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition

scientific article published in March 2015

The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy

scientific article

The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line

scientific article published on February 2004

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3

scientific article

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.

scientific article published on January 2004

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).

scientific article published on 2 November 2007

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions

scientific article published on 01 April 2000

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

scientific article published in May 1994

Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro ⬇️

scientific article published on 01 July 1998

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.

scientific article

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

scientific article published in 2021

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours

scientific article published on 8 February 2021

Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts

scientific article published on September 2003

Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence

scientific article

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.

scientific article published on 19 August 2010

Paulina is supported by:

About Paulina

Help